 | • レポートコード：MRCLP3DB4950 • 出版社/出版日：LP Information / 2023年12月 • レポート形態：英文、PDF、101ページ • 納品方法：Eメール（納期：2-3営業日） • 産業分類：医薬品＆医療 |
| Single User | ￥549,000 (USD3,660) | ▷ お問い合わせ |
| Corporate User | ￥1,098,000 (USD7,320) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| LPインフォメーション社の最新調査レポート「処方減量薬の世界市場」は、過去の販売実績から2022年の世界の処方減量薬の総販売量を検討し、2023年から2029年の予測される処方減量薬の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の処方減量薬の市場規模を掲載し、XXX百万米ドル規模の世界の処方減量薬市場の詳細な分析を提供します。本インサイトレポートは、世界の処方減量薬業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。 また、本資料では、加速する世界の処方減量薬市場における各社の独自のポジションをより深く理解するために、処方減量薬製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。 世界の処方減量薬市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。処方減量薬の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。処方減量薬の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。処方減量薬の欧州市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。 処方減量薬の世界主要メーカーとしては、Currax Pharmaceuticals (Contrave)、 VIVUS (Qsymia)、 Novo Nordisk A/S、 Rhythm Pharmaceuticals (Imcivree)、 Eli Lilly and Company (TRICARE)、 CHEPLAPHARM (Xenical)、 Pfizer、 Teva Pharmaceutical (Actavis)、 Haleon Group (alli)、 Sanofi (Adlyxin)、 AstraZeneca (BYDUREON BCise)などを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。 本調査資料では、製品タイプ、用途、主要メーカー、主要地域、国別の処方減量薬市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。 【市場細分化】 本調査では処方減量薬市場をセグメンテーションし、種類別 (経口錠、経口カプセル、注射剤)、用途別 (病院、薬局)、および地域別 (アジア太平洋、南北アメリカ、欧州、および中東・アフリカ) の市場規模を予測しています。 ・種類別区分：経口錠、経口カプセル、注射剤 ・用途別区分：病院、薬局 ・地域別区分 南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル） アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア） 欧州（ドイツ、フランス、イギリス、イタリア、ロシア） 中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国） 【本レポートで扱う主な質問】 ・世界の処方減量薬市場の10年間の市場状況・展望は？ ・世界および地域別に見た処方減量薬市場成長の要因は何か？ ・処方減量薬の市場機会はエンドマーケットの規模によってどのように変化するのか？ ・処方減量薬のタイプ別、用途別の内訳は？ ・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？ ********* 目次 ********* レポートの範囲 ・市場の紹介 ・分析対象期間 ・調査の目的 ・調査手法 ・調査プロセスおよびデータソース ・経済指標 ・通貨 エグゼクティブサマリー ・世界市場の概要：処方減量薬の年間販売量2018-2029、地域別現状・将来分析 ・処方減量薬の種類別セグメント：経口錠、経口カプセル、注射剤 ・処方減量薬の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格 ・処方減量薬の用途別セグメント：病院、薬局 ・処方減量薬の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格 企業別世界の処方減量薬市場 ・企業別のグローバル処方減量薬市場データ：2018-2023年の年間販売量、市場シェア ・企業別の処方減量薬の年間売上：2018-2023年の売上、市場シェア ・企業別の処方減量薬販売価格 ・主要企業の処方減量薬生産地域、販売地域、製品タイプ ・市場集中度分析 ・新製品および潜在的な参加者 ・合併と買収、拡大 処方減量薬の地域別レビュー ・地域別の処方減量薬市場規模2018-2023：年間販売量、売上 ・主要国別の処方減量薬市場規模2018-2023：年間販売量、売上 ・南北アメリカの処方減量薬販売の成長 ・アジア太平洋の処方減量薬販売の成長 ・欧州の処方減量薬販売の成長 ・中東・アフリカの処方減量薬販売の成長 南北アメリカ市場 ・南北アメリカの国別の処方減量薬販売量、売上（2018-2023） ・南北アメリカの処方減量薬の種類別販売量 ・南北アメリカの処方減量薬の用途別販売量 ・アメリカ市場 ・カナダ市場 ・メキシコ市場 ・ブラジル市場 アジア太平洋市場 ・アジア太平洋の国別の処方減量薬販売量、売上（2018-2023） ・アジア太平洋の処方減量薬の種類別販売量 ・アジア太平洋の処方減量薬の用途別販売量 ・中国市場 ・日本市場 ・韓国市場 ・東南アジア市場 ・インド市場 ・オーストラリア市場 ・台湾市場 欧州市場 ・欧州の国別の処方減量薬販売量、売上（2018-2023） ・欧州の処方減量薬の種類別販売量 ・欧州の処方減量薬の用途別販売量 ・ドイツ市場 ・フランス市場 ・イギリス市場 ・イタリア市場 ・ロシア市場 中東・アフリカ市場 ・中東・アフリカの国別の処方減量薬販売量、売上（2018-2023） ・中東・アフリカの処方減量薬の種類別販売量 ・中東・アフリカの処方減量薬の用途別販売量 ・エジプト市場 ・南アフリカ市場 ・イスラエル市場 ・トルコ市場 ・GCC諸国市場 市場の成長要因、課題、動向 ・市場の成長要因および成長機会分析 ・市場の課題およびリスク ・市場動向 製造コスト構造分析 ・原材料とサプライヤー ・処方減量薬の製造コスト構造分析 ・処方減量薬の製造プロセス分析 ・処方減量薬の産業チェーン構造 マーケティング、販売業者および顧客 ・販売チャンネル：直接販売チャンネル、間接販売チャンネル ・処方減量薬の主要なグローバル販売業者 ・処方減量薬の主要なグローバル顧客 地域別の処方減量薬市場予測レビュー ・地域別の処方減量薬市場規模予測（2024-2029） ・南北アメリカの国別予測 ・アジア太平洋の国別予測 ・欧州の国別予測 ・処方減量薬の種類別市場規模予測 ・処方減量薬の用途別市場規模予測 主要企業分析 Currax Pharmaceuticals (Contrave)、 VIVUS (Qsymia)、 Novo Nordisk A/S、 Rhythm Pharmaceuticals (Imcivree)、 Eli Lilly and Company (TRICARE)、 CHEPLAPHARM (Xenical)、 Pfizer、 Teva Pharmaceutical (Actavis)、 Haleon Group (alli)、 Sanofi (Adlyxin)、 AstraZeneca (BYDUREON BCise) ・企業情報 ・処方減量薬製品 ・処方減量薬販売量、売上、価格、粗利益（2018-2023） ・主要ビジネス概要 ・最新動向 調査結果および結論 |
The global Prescription Weight Loss Pills market size is projected to grow from US$ 1105.4 million in 2022 to US$ 2264.6 million in 2029; it is expected to grow at a CAGR of 10.8% from 2023 to 2029.
United States market for Prescription Weight Loss Pills is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Prescription Weight Loss Pills is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Prescription Weight Loss Pills is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Prescription Weight Loss Pills players cover Currax Pharmaceuticals (Contrave), VIVUS (Qsymia), Novo Nordisk A/S, Rhythm Pharmaceuticals (Imcivree), Eli Lilly and Company (TRICARE), CHEPLAPHARM (Xenical), Pfizer, Teva Pharmaceutical (Actavis) and Haleon Group (alli), etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Health care professionals use the Body Mass Index (BMI), a measure of people weight in relation to height, to define overweight and obesity. People who have a BMI between 25 and 30 are considered to be overweight. Obesity is defined as having a BMI of 30 or greater. Are overweight, obese, or severely obese, which may increase risk of developing health problems. Obesity is a chronic disease and prescription medications to treat overweight and obesity work in different ways. Prescription weight loss medicines can help obese people lose weight. They are usually prescribed by a doctor when diet and exercise alone are not working. Each of these medicines works differently. People who use these medicines may not feel as hungry. Or they may feel full after eating only a small amount of food. Another type of weight-loss medicine makes it harder for your body to absorb fat. Prescription weight loss drugs can be helpful when used in combination with a low-calorie diet and regular physical activity.
LPI (LP Information)’ newest research report, the “Prescription Weight Loss Pills Industry Forecast” looks at past sales and reviews total world Prescription Weight Loss Pills sales in 2022, providing a comprehensive analysis by region and market sector of projected Prescription Weight Loss Pills sales for 2023 through 2029. With Prescription Weight Loss Pills sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Prescription Weight Loss Pills industry.
This Insight Report provides a comprehensive analysis of the global Prescription Weight Loss Pills landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Prescription Weight Loss Pills portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Prescription Weight Loss Pills market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Prescription Weight Loss Pills and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Prescription Weight Loss Pills.
This report presents a comprehensive overview, market shares, and growth opportunities of Prescription Weight Loss Pills market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Oral Tablets
Oral Capsules
Injections
Segmentation by application
Hospital
Pharmacy
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Currax Pharmaceuticals (Contrave)
VIVUS (Qsymia)
Novo Nordisk A/S
Rhythm Pharmaceuticals (Imcivree)
Eli Lilly and Company (TRICARE)
CHEPLAPHARM (Xenical)
Pfizer
Teva Pharmaceutical (Actavis)
Haleon Group (alli)
Sanofi (Adlyxin)
AstraZeneca (BYDUREON BCise)
Key Questions Addressed in this Report
What is the 10-year outlook for the global Prescription Weight Loss Pills market?
What factors are driving Prescription Weight Loss Pills market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Prescription Weight Loss Pills market opportunities vary by end market size?
How does Prescription Weight Loss Pills break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Prescription Weight Loss Pills Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Prescription Weight Loss Pills by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Prescription Weight Loss Pills by Country/Region, 2018, 2022 & 2029
2.2 Prescription Weight Loss Pills Segment by Type
2.2.1 Oral Tablets
2.2.2 Oral Capsules
2.2.3 Injections
2.3 Prescription Weight Loss Pills Sales by Type
2.3.1 Global Prescription Weight Loss Pills Sales Market Share by Type (2018-2023)
2.3.2 Global Prescription Weight Loss Pills Revenue and Market Share by Type (2018-2023)
2.3.3 Global Prescription Weight Loss Pills Sale Price by Type (2018-2023)
2.4 Prescription Weight Loss Pills Segment by Application
2.4.1 Hospital
2.4.2 Pharmacy
2.5 Prescription Weight Loss Pills Sales by Application
2.5.1 Global Prescription Weight Loss Pills Sale Market Share by Application (2018-2023)
2.5.2 Global Prescription Weight Loss Pills Revenue and Market Share by Application (2018-2023)
2.5.3 Global Prescription Weight Loss Pills Sale Price by Application (2018-2023)
3 Global Prescription Weight Loss Pills by Company
3.1 Global Prescription Weight Loss Pills Breakdown Data by Company
3.1.1 Global Prescription Weight Loss Pills Annual Sales by Company (2018-2023)
3.1.2 Global Prescription Weight Loss Pills Sales Market Share by Company (2018-2023)
3.2 Global Prescription Weight Loss Pills Annual Revenue by Company (2018-2023)
3.2.1 Global Prescription Weight Loss Pills Revenue by Company (2018-2023)
3.2.2 Global Prescription Weight Loss Pills Revenue Market Share by Company (2018-2023)
3.3 Global Prescription Weight Loss Pills Sale Price by Company
3.4 Key Manufacturers Prescription Weight Loss Pills Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Prescription Weight Loss Pills Product Location Distribution
3.4.2 Players Prescription Weight Loss Pills Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Prescription Weight Loss Pills by Geographic Region
4.1 World Historic Prescription Weight Loss Pills Market Size by Geographic Region (2018-2023)
4.1.1 Global Prescription Weight Loss Pills Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Prescription Weight Loss Pills Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Prescription Weight Loss Pills Market Size by Country/Region (2018-2023)
4.2.1 Global Prescription Weight Loss Pills Annual Sales by Country/Region (2018-2023)
4.2.2 Global Prescription Weight Loss Pills Annual Revenue by Country/Region (2018-2023)
4.3 Americas Prescription Weight Loss Pills Sales Growth
4.4 APAC Prescription Weight Loss Pills Sales Growth
4.5 Europe Prescription Weight Loss Pills Sales Growth
4.6 Middle East & Africa Prescription Weight Loss Pills Sales Growth
5 Americas
5.1 Americas Prescription Weight Loss Pills Sales by Country
5.1.1 Americas Prescription Weight Loss Pills Sales by Country (2018-2023)
5.1.2 Americas Prescription Weight Loss Pills Revenue by Country (2018-2023)
5.2 Americas Prescription Weight Loss Pills Sales by Type
5.3 Americas Prescription Weight Loss Pills Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Prescription Weight Loss Pills Sales by Region
6.1.1 APAC Prescription Weight Loss Pills Sales by Region (2018-2023)
6.1.2 APAC Prescription Weight Loss Pills Revenue by Region (2018-2023)
6.2 APAC Prescription Weight Loss Pills Sales by Type
6.3 APAC Prescription Weight Loss Pills Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Prescription Weight Loss Pills by Country
7.1.1 Europe Prescription Weight Loss Pills Sales by Country (2018-2023)
7.1.2 Europe Prescription Weight Loss Pills Revenue by Country (2018-2023)
7.2 Europe Prescription Weight Loss Pills Sales by Type
7.3 Europe Prescription Weight Loss Pills Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Prescription Weight Loss Pills by Country
8.1.1 Middle East & Africa Prescription Weight Loss Pills Sales by Country (2018-2023)
8.1.2 Middle East & Africa Prescription Weight Loss Pills Revenue by Country (2018-2023)
8.2 Middle East & Africa Prescription Weight Loss Pills Sales by Type
8.3 Middle East & Africa Prescription Weight Loss Pills Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Prescription Weight Loss Pills
10.3 Manufacturing Process Analysis of Prescription Weight Loss Pills
10.4 Industry Chain Structure of Prescription Weight Loss Pills
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Prescription Weight Loss Pills Distributors
11.3 Prescription Weight Loss Pills Customer
12 World Forecast Review for Prescription Weight Loss Pills by Geographic Region
12.1 Global Prescription Weight Loss Pills Market Size Forecast by Region
12.1.1 Global Prescription Weight Loss Pills Forecast by Region (2024-2029)
12.1.2 Global Prescription Weight Loss Pills Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Prescription Weight Loss Pills Forecast by Type
12.7 Global Prescription Weight Loss Pills Forecast by Application
13 Key Players Analysis
13.1 Currax Pharmaceuticals (Contrave)
13.1.1 Currax Pharmaceuticals (Contrave) Company Information
13.1.2 Currax Pharmaceuticals (Contrave) Prescription Weight Loss Pills Product Portfolios and Specifications
13.1.3 Currax Pharmaceuticals (Contrave) Prescription Weight Loss Pills Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Currax Pharmaceuticals (Contrave) Main Business Overview
13.1.5 Currax Pharmaceuticals (Contrave) Latest Developments
13.2 VIVUS (Qsymia)
13.2.1 VIVUS (Qsymia) Company Information
13.2.2 VIVUS (Qsymia) Prescription Weight Loss Pills Product Portfolios and Specifications
13.2.3 VIVUS (Qsymia) Prescription Weight Loss Pills Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 VIVUS (Qsymia) Main Business Overview
13.2.5 VIVUS (Qsymia) Latest Developments
13.3 Novo Nordisk A/S
13.3.1 Novo Nordisk A/S Company Information
13.3.2 Novo Nordisk A/S Prescription Weight Loss Pills Product Portfolios and Specifications
13.3.3 Novo Nordisk A/S Prescription Weight Loss Pills Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Novo Nordisk A/S Main Business Overview
13.3.5 Novo Nordisk A/S Latest Developments
13.4 Rhythm Pharmaceuticals (Imcivree)
13.4.1 Rhythm Pharmaceuticals (Imcivree) Company Information
13.4.2 Rhythm Pharmaceuticals (Imcivree) Prescription Weight Loss Pills Product Portfolios and Specifications
13.4.3 Rhythm Pharmaceuticals (Imcivree) Prescription Weight Loss Pills Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Rhythm Pharmaceuticals (Imcivree) Main Business Overview
13.4.5 Rhythm Pharmaceuticals (Imcivree) Latest Developments
13.5 Eli Lilly and Company (TRICARE)
13.5.1 Eli Lilly and Company (TRICARE) Company Information
13.5.2 Eli Lilly and Company (TRICARE) Prescription Weight Loss Pills Product Portfolios and Specifications
13.5.3 Eli Lilly and Company (TRICARE) Prescription Weight Loss Pills Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Eli Lilly and Company (TRICARE) Main Business Overview
13.5.5 Eli Lilly and Company (TRICARE) Latest Developments
13.6 CHEPLAPHARM (Xenical)
13.6.1 CHEPLAPHARM (Xenical) Company Information
13.6.2 CHEPLAPHARM (Xenical) Prescription Weight Loss Pills Product Portfolios and Specifications
13.6.3 CHEPLAPHARM (Xenical) Prescription Weight Loss Pills Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 CHEPLAPHARM (Xenical) Main Business Overview
13.6.5 CHEPLAPHARM (Xenical) Latest Developments
13.7 Pfizer
13.7.1 Pfizer Company Information
13.7.2 Pfizer Prescription Weight Loss Pills Product Portfolios and Specifications
13.7.3 Pfizer Prescription Weight Loss Pills Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Pfizer Main Business Overview
13.7.5 Pfizer Latest Developments
13.8 Teva Pharmaceutical (Actavis)
13.8.1 Teva Pharmaceutical (Actavis) Company Information
13.8.2 Teva Pharmaceutical (Actavis) Prescription Weight Loss Pills Product Portfolios and Specifications
13.8.3 Teva Pharmaceutical (Actavis) Prescription Weight Loss Pills Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 Teva Pharmaceutical (Actavis) Main Business Overview
13.8.5 Teva Pharmaceutical (Actavis) Latest Developments
13.9 Haleon Group (alli)
13.9.1 Haleon Group (alli) Company Information
13.9.2 Haleon Group (alli) Prescription Weight Loss Pills Product Portfolios and Specifications
13.9.3 Haleon Group (alli) Prescription Weight Loss Pills Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Haleon Group (alli) Main Business Overview
13.9.5 Haleon Group (alli) Latest Developments
13.10 Sanofi (Adlyxin)
13.10.1 Sanofi (Adlyxin) Company Information
13.10.2 Sanofi (Adlyxin) Prescription Weight Loss Pills Product Portfolios and Specifications
13.10.3 Sanofi (Adlyxin) Prescription Weight Loss Pills Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Sanofi (Adlyxin) Main Business Overview
13.10.5 Sanofi (Adlyxin) Latest Developments
13.11 AstraZeneca (BYDUREON BCise)
13.11.1 AstraZeneca (BYDUREON BCise) Company Information
13.11.2 AstraZeneca (BYDUREON BCise) Prescription Weight Loss Pills Product Portfolios and Specifications
13.11.3 AstraZeneca (BYDUREON BCise) Prescription Weight Loss Pills Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 AstraZeneca (BYDUREON BCise) Main Business Overview
13.11.5 AstraZeneca (BYDUREON BCise) Latest Developments
14 Research Findings and Conclusion